First oral therapy for frontotemporal degeneration shows promise
Positive topline results from Vesper Bio’s Phase Ib/IIa SORT-IN-2 clinical study evaluating VES001 in asymptomatic carriers with frontotemporal degeneration (FTD) caused by mutations in the progranulin gene (GRN).
Mean progranulin levels increased by more than 95% compared to baseline at the highest dose tested.
As individuals with FTD-GRN typically have progranulin concentrations that are around half that of people without GRN mutations, this represents a normalising of progranulin levels.
Mads Kjolby, Co-Founder and Chief Medical Officer at Vesper Bio, said: “Based on these topline Phase Ib/IIa data, we believe VES001 has the potential to normalise progranulin levels not only in asymptomatic individuals with GRN mutations, but in symptomatic people too, without affecting other sortilin functions crucial for neuronal health. We therefore think VES001 has great potential to slow or even arrest FTD-GRN disease progression.”
The study demonstrated that VES001 had a safe and tolerable profile. It also confirmed target engagement took place, with significantly elevated levels of progranulin in both plasma and CSF found in the participants after treatment, compared to baseline levels of the protein for this population.
The findings provide the first validation of Vesper’s approach of restoring normal progranulin levels in this population by selectively inhibiting progranulin binding to the sortilin receptor without affecting sortilin levels or functions important for neuronal health. This is in contrast to antibody-mediated degradation of sortilin.
Professor Jonathan Rohrer, of the Dementia Research Centre, UCL Queen Square Institute of Neurology, London, UK, Principal Investigator at the trial’s UK sites, said: “This is the first oral therapy being tested in FTD. The increase of progranulin levels back to normal levels in these asymptomatic mutation carriers – who know they will develop symptoms in the next 10 to 20 years – speaks to the future potential of this treatment to prevent people ever developing symptoms of FTD.”
Diana Turner, Deputy Editor, DDW
